Literature DB >> 10375108

Synovial sarcoma: identification of low and high risk groups.

P Bergh1, J M Meis-Kindblom, F Gherlinzoni, O Berlin, P Bacchini, F Bertoni, B Gunterberg, L G Kindblom.   

Abstract

BACKGROUND: Synovial sarcoma, one of the most common soft tissue sarcomas that occur in adolescents and young adults, is generally viewed and treated as a high grade sarcoma. However, the authors' own experience and some previous studies have indicated that it has a wide spectrum of biologic behavior and that low and high risk subgroups of patients with synovial sarcoma can be identified.
METHODS: A total of 121 consecutive patients with synovial sarcoma (including 66 males and 55 females ages 9-74 years), treated primarily or secondarily at 2 large referral centers for musculoskeletal tumors, were included in a statistical analysis conducted to identify independent prognostic factors.
RESULTS: There were local recurrences in 38 patients (31%), usually after inadequate primary surgery outside the referral centers; 64 patients (54%) developed metastasis, primarily to the lungs. The estimated 5-, 10-, and 15-year survival rates were 60%, 50%, and 45%, respectively (the mean follow-up for surviving patients was 9.8 years, with a range of 1-30 years). In multivariate analysis, independent risk factors for local recurrence included larger tumor size and primary surgical resection outside the referral center. Independent risk factors for metastasis were older patient age, tumor with poor histologic differentiation, and tumor necrosis. For tumor-related death, the independent risk factors were older patient age, tumor with poor histologic differentiation, and larger tumor size. Local recurrence was associated with a 3.66-fold increased risk of tumor-related death. A low risk group (patient age <25 years, tumor size <5 cm, and no histologic evidence of poorly differentiated tumor) with 88% overall disease free survival was identified, as was a high risk group (patient age > or = 25 years, tumor size > or = 5 cm, and poorly differentiated tumor) with 18% overall disease free survival (P < 0.001).
CONCLUSIONS: The identification of low and high risk synovial sarcoma patients indicates that synovial sarcomas are not uniformly high grade tumors. It also indicates that treatment strategies should be modified for these risk groups. Adequate primary surgery is essential to both local control and outcome for synovial sarcoma patients.

Entities:  

Mesh:

Year:  1999        PMID: 10375108     DOI: 10.1002/(sici)1097-0142(19990615)85:12<2596::aid-cncr16>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  64 in total

1.  Her-2 oncogene amplification, chromosome 17 and DNA ploidy status in synovial sarcoma.

Authors:  Zoltán Sápi; Zsuzsa Pápai; Anett Hruska; Imre Antal; Miklós Bodó; Zsolt Orosz
Journal:  Pathol Oncol Res       Date:  2005-09-29       Impact factor: 3.201

2.  Expert's comment concerning Grand Rounds case entitled "synovial sarcoma of the spine: a case involving paraspinal muscle with extensive calcification and the surgical consideration in treatment" (by Junhyung Kim, Sun-Ho Lee, Yoon-La Choi, Go Eun Bae, Eun-Sang Kim, Whan Eoh).

Authors:  Robert U Ashford
Journal:  Eur Spine J       Date:  2013-06-29       Impact factor: 3.134

3.  Enhancer of zeste homologue 2 (EZH2) expression in synovial sarcomas as a promising indicator of prognosis.

Authors:  Ulviye Yalçınkaya; Nesrin Uğraş; Gonca Özgün; Gökhan Ocakoğlu; Adem Deligönül; Sibel Kahraman Çetintaş; Muhammed Sadık Bilgen
Journal:  Bosn J Basic Med Sci       Date:  2017-11-20       Impact factor: 3.363

Review 4.  Molecular and clinicopathological findings in a tonsillar synovial sarcoma. A case study and review of the literature.

Authors:  U Vogel; M Wehrmann; W Eichhorn; B Bültmann; M Stiegler; W Wagner
Journal:  Head Neck Pathol       Date:  2010-07-13

5.  Detection of SYT-SSX fusion transcripts in archival synovial sarcomas by real-time reverse transcriptase-polymerase chain reaction.

Authors:  Karen E Bijwaard; John F Fetsch; Ronald Przygodzki; Jeffery K Taubenberger; Jack H Lichy
Journal:  J Mol Diagn       Date:  2002-02       Impact factor: 5.568

6.  Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines.

Authors:  Toshinori Sakai; Ramez N Eskander; Yi Guo; Kap Jung Kim; Jason Mefford; Justin Hopkins; Nitin N Bhatia; Xiaolin Zi; Bang H Hoang
Journal:  J Orthop Res       Date:  2011-12-29       Impact factor: 3.494

7.  Prognostic factors that govern localized synovial sarcoma: a single institution retrospective study on 51 patients.

Authors:  Sameer Yaser; Samer Salah; Marwa Al-Shatti; Areej Abu-Sheikha; Ahmad Shehadeh; Iyad Sultan; Ahmad Salem; Maher Sughayer; Shaymaa Al-Loh; Abdelatif Al-Mousa
Journal:  Med Oncol       Date:  2014-04-26       Impact factor: 3.064

8.  Intraneural synovial sarcoma of the median nerve.

Authors:  Angelo B Lipira; Rahul Kasukurthi; Wilson Z Ray; Mark E Pruzansky; Susan E Mackinnon
Journal:  Rare Tumors       Date:  2010-06-30

9.  Risk assessment based on FDG-PET imaging in patients with synovial sarcoma.

Authors:  Jennifer W Lisle; Janet F Eary; Janet O'Sullivan; Ernest U Conrad
Journal:  Clin Orthop Relat Res       Date:  2008-12-02       Impact factor: 4.176

10.  Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas.

Authors:  Christine G Joseph; Heejung Hwang; Yuchen Jiao; Laura D Wood; Isaac Kinde; Jian Wu; Nils Mandahl; Jinyong Luo; Ralph H Hruban; Luis A Diaz; Tong-Chuan He; Bert Vogelstein; Kenneth W Kinzler; Fredrik Mertens; Nickolas Papadopoulos
Journal:  Genes Chromosomes Cancer       Date:  2013-11-05       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.